Heather Wakelee
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior to starting KRAS G12Ci; C) Survival outcomes according to PD-L1 status (TPS: tumor proportion score); D) survival outcomes in patients with or without prior immune checkpoint inhibitor therapy.
Year:
2025
A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.
Year:
2025
Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.
Year:
2025
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.
Year:
2025
Figures showing the CONSORT diagram, clonal hematopoiesis prevalence, the SNV score model, mid-chemoradiation ctDNA analysis, radiomic model robustness, pre-chemoradiation prognostic factors, association of clonal hematopoiesis with outcomes, and association of the CIRI-LCRT model with progression-free survival.
Year:
2025
The complementarity and clinical utility of combining liquid biopsies and radiomic image analysis has not been demonstrated. ctDNA minimal residual disease after chemoradiotherapy (CRT) for non–small cell lung cancer (NSCLC) is highly prognostic, but on-treatment biomarkers are needed to enable response-adapted therapies. In this study, we analyzed 418 patients with NSCLC undergoing CRT to develop and validate a novel dynamic risk model that accurately predicts ultimate progression-free survival during treatment. We optimize tissue-free variant calling from plasma samples to facilitate ctDNA monitoring and demonstrate the importance of accounting for persistent clonal hematopoiesis variants. We show that mid-CRT ctDNA concentration is prognostic for disease progression and integrate additional pre-CRT risk factors, including radiomics, into a combined model that improves outcome prediction. Our results suggest that tumor features, radiomics, and mid-CRT ctDNA analysis are complementary and can identify patients at high and low risk of progression to potentially enable response-adapted therapies. Significance: This study demonstrates that combining tumor features, radiomics, and ctDNA analysis improves outcome prediction in NSCLC treated with CRT therapy. Our integrated model could enable personalized and response-adapted therapies to reduce toxicity and improve outcomes in patients. See related commentary by Anagnostou and Aggarwal, p. 1534
Year:
2025
A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior to starting KRAS G12Ci; C) Survival outcomes according to PD-L1 status (TPS: tumor proportion score); D) survival outcomes in patients with or without prior immune checkpoint inhibitor therapy.
Year:
2024
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.
Year:
2024
A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.
Year:
2024
A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (40)
Mark Awad
Chief, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Neal Akhave
Assistant Professor
The University of Texas MD Anderson Cancer Center
Christine Bestvina
Assistant Professor
University of Chicago Medicine
Sandip Patel
Associate Professor
Moores Cancer Center, UC San Diego Health
Marina Garassino
Prof
Università degli Studi di Torino
Jacobi Hines
Assistant Professor
Northwestern Medicine
Qi Wang
The University of Texas MD Anderson Cancer Center
Mizuki Nishino
King’s College London
Petros Christopoulos
-
Yufei Liu
Assistant Clinical Professor
City of Hope
Everett J. Moding
Stanford University
Amy L Cummings
UCLA School of Medicine
Ruijiang Li
Associate Professor
Stanford University
Giorgio V Scagliotti
Chair
University of Turin
james hicks
H Lee Moffitt Cancer Center and Research Institute
Arash Ash Alizadeh
Professor of Medicine
Stanford University School of Medicine
Mingjia Li
Assistant Professor
Ohio State University
Maximilian Diehn
Professor
Stanford University
Collin Blakely
Assistant Professor
UCSF Medical Center
Matthias Scheffler
University Hospital Bonn
Kavitha Ramchandran
Clinical Associate Professor
Stanford University
John V. Heymach
The University of Texas MD Anderson Cancer Center
J. Jack Lee
Professor
The University of Texas MD Anderson Cancer Center
Aadel A. Chaudhuri
Washington University School of Medicine
Steven Lin
Professor
The University of Texas MD Anderson Cancer Center
Jing Wang
Professor
The University of Texas MD Anderson Cancer Center
David S. Hong
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
David Kurtz
Assistant Professor
Stanford University
Ying Ni
Assistant Professor
Case Western Reserve University
Catherine Shu
Columbia University Irving Medical Center
Ferdinandos Skoulidis
The University of Texas MD Anderson Cancer Center
Albrecht Stenzinger
-
Billy Loo
Professor
Stanford University
Michael F. Gensheimer
Stanford University School of Medicine
Marcelo Negrao
Assistant Professor
The University of Texas MD Anderson Cancer Center
Don L. Gibbons
The University of Texas MD Anderson Cancer Center
Dwight H. Owen
Ohio State University
Mohammad Shahrokh Esfahani
Assistant Professor
Stanford University
Make your next move.
Prepare your application
Review drafts before you send them.